Avid Bioservices Inc (CDMO)

[biopharm]

Hakan Mellstedt : Peregrine Pharmaceuticals KOL

.... ok, so lately we've brought in some puzzle pieces for Greg Lemke <> Xetrios <> Salks Institute and a PS Targeting Patent and all other associated patents of Lemkes's and Salks all sold to "Kolltan"

so the puzzle gets bigger but at least we have a tie from Hakan Mellstedt to Gerald McMahon CEO of Kolltan...and PAV lists of some have shown Standish Fleming as well

...
...
..

I post this, because I remember the very first time I seen that Greg Lemke/Salk was studying/researching PS Targeting and the first time I seen Phosphatidylserine written as "PtdSer" was with Salks publications by Greg Lemke. Anyhow, as you can see all their patents / research..etc was purchased by KOLLTAN.

Kolltan CEO McMahon speaks a couple hours after Jeff Hutchins next week and notice how it states "..and their cognate ligands" ?? Seems like it could be referring to PS receptors and all that PS Targeting research that fell in the hands of Kolltan and now Kolltan one of the very few at this conference must truly know that PS Targeting is required for that optimal immune response.

Combination Immunotherapy Strategies


8:25 Chairperson’s Opening Remarks

Jeff T. Hutchins, Ph.D., Vice President, Preclinical Research, Peregrine Pharmaceuticals


Michael A. Postow
8:30 Immune Checkpoint Modulation: Rational Design of Combination Strategies

Michael A. Postow, M.D., Assistant Attending Physician, Melanoma and Immunotherapeutics Service, Memorial Sloan-Kettering Cancer Center

The immune system can be manipulated to enhance antitumor immunity. Efficacy has been demonstrated by approaches that block immune checkpoints, but not all patients benefit from treatment and improved outcomes are needed. Therapeutic approaches combining multiple immune checkpoint inhibitors with standard anticancer agents (radiotherapy, targeted therapy, and chemotherapy) are of great interest. Current approaches and a framework for the future will be discussed.


Jeff T. Hutchins
9:00 Expansion and Activation of T Cells via the Targeting of the Immunosuppressive Ligand Phosphatidylserine (PS): Combination Strategy with Conventional, Targeted, and Checkpoint Inhibitor Therapy

Jeff T. Hutchins, Ph.D., Vice President, Preclinical Research, Peregrine Pharmaceuticals

The underlying cause for the failure of current therapies is the persistent and multifocal immune suppression in the tumor microenvironment that drives the absence of pre-existing antitumor T cells. Bavituximab blocks PS-mediated immunosuppression (decreasing MDSCs) by reprograming immune cells in the tumor microenvironment to enhance anticancer activity. Pre-clinical, translational, and clinical results using bavituximab with conventional and immunotherapy combinations promotes a robust, anti-tumor T cell mediated response to enhance cancer therapy.
...
...
...

11:30 The TAM Receptor Tyrosine Kinase Family and Their Potential to Modulate Macrophage and Dendritic Cell Function Create Opportunities to Combine with T Cell Checkpoint Drugs

Jerry McMahon, Ph.D., President & CEO, Kolltan Pharmaceuticals

TAM receptor tyrosine kinases and their cognate ligands play a key role in immune homeostasis through signaling in macrophage and dendritic cells and regulating the adaptive immune response. Modulation of the activation of these receptors may up- or down-regulate immune homeostasis for the treatment of cancer and other diseases. Inhibition of Axl and MerTK are under investigation to potentiate the effectiveness of biologic agents that interfere with T cell checkpoints in tumor immunology.

12:00 pm Late-Breaking Presentation

...
..

http://www.imvacs.com/Combination-Cancer-Immunotherapy/